Literature DB >> 17186203

Should we really worry about "launch delays" of new drugs in OECD countries?

Livio Garattini, Simone Ghislandi.   

Abstract

Mesh:

Year:  2007        PMID: 17186203     DOI: 10.1007/s10198-006-0022-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


× No keyword cloud information.
  8 in total

1.  Do (more and better) drugs keep people out of hospitals?

Authors:  F R Lichtenberg
Journal:  Am Econ Rev       Date:  1996-05

2.  A review of new drugs and indications in 2002: financial speculation or better patent care?

Authors: 
Journal:  Prescrire Int       Date:  2003-04

3.  Drug sales in four European countries still differ.

Authors:  Silvio Garattini; Livio Garattini
Journal:  BMJ       Date:  2003-12-13

4.  The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.

Authors:  Patricia M Danzon; Y Richard Wang; Liang Wang
Journal:  Health Econ       Date:  2005-03       Impact factor: 3.046

5.  Examining the link between price regulation and pharmaceutical R&D investment.

Authors:  John A Vernon
Journal:  Health Econ       Date:  2005-01       Impact factor: 3.046

Review 6.  Disappointing biotech.

Authors:  Roberta Joppi; Vittorio Bertele'; Silvio Garattini
Journal:  BMJ       Date:  2005-10-15

7.  The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

Authors:  Frank R Lichtenberg
Journal:  Int J Health Care Finance Econ       Date:  2005-03

8.  Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.

Authors:  G Apolone; R Joppi; V Bertele'; S Garattini
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

  8 in total
  4 in total

1.  Comment on: Should we really worry about "launch delays" of new drugs in OECD countries? by L. Garatinni and S. Ghislandi.

Authors:  Joshua Cohen
Journal:  Eur J Health Econ       Date:  2007-06

2.  Assessing the impact of global price interdependencies.

Authors:  Anke Richter
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Examining the determinants of drug launch delay in pre-TRIPS India.

Authors:  Saradindu Bhaduri; Thomas Brenner
Journal:  Eur J Health Econ       Date:  2012-09-09

4.  Does health technology assessment compromise access to pharmaceuticals?

Authors:  Melanie Büssgen; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2022-06-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.